34^th Annual European Pharma Congress

Dr. Bimal Roy Krishna is currently Professor and Director of Pharmacology at the College of Osteopathic Medicine, Touro University in Nevada. He obtained a Bachelor of Science (First Class Honors) in Pharmacology and Physiology and a Doctor of Philosophy, Medicine (OB/GYN/Pharmacology) from Monash University in Australia. Dr. Krishna also teaches for the Step 1 USMLE and COMLEX reviews for Kaplan Medical throughout the United States and in UAE, Europe, Saudi Arabia, India, Mexico and the Caribbean. He has been teaching online for Kaplan University for over 7 years. He has contributed to numerous publications and is a member of a number of organizations including Fellow-American College of Clinical Pharmacology.

His research background is in maternal and neonatal pharmacology specifically looking at materno-fetal transfer utilizing the perfused human placental and cultured syncytiotrophoblast model. Complementary and Alternative medicine is another area of interest.

The author received an honorable PhD in mathematics and majored in engineering at MIT. He attended different universities over 17 years and studied seven academic disciplines. He has spent 20,000 hours in T2D research. First, he studied six metabolic diseases and food nutrition during 2010-2013, then conducted research during 2014-2018. His approach is “math-physics and quantitative medicine” based on mathematics, physics, engineering modeling, signal processing, computer science, big data analytics, statistics, machine learning, and AI. His main focus is on preventive medicine using prediction tools. He believes that the better the prediction, the more control you have.

The author spent seven years and 18,000 hours to study, analyze and research his chronic disease conditions. Here is the comparison between 2010 and 2017: Weight: 205 / 172 lbs. Waistline: 44 / 34 inches PPG: 350 / 116 mg/dL FPG: 185 / 119 mg/dL Daily glucose: 280 / 117 mg/dL A1C: 10.0 / 6.1 % ACR: 116 / 12 mg/mmol Triglycerides: 1161 / 69 mg/dL He used mathematics, physics, engineering modeling, and computer science (big data analytics and AI) to derive the mathematical metabolism model and three prediction tools for weight, FPG, and PPG with >30 input elements. This study includes 11 categories: weight, glucose, blood pressure, lipids, food, water, exercise, sleep, stress, life pattern regularity, time, with ~500 input and output elements. He collected more than 1 million “clean” data over 7 years. He defined two new terms known as the Metabolism Index (MI) and General Health Status Unit (GHSU). The “health state” is expressed as the “break-even” line which is 73.5%; above this percentage is regarded “unhealthy” and below the break-even line is “healthy”. The results showed that he was very unhealthy (80%-110%) before 2013. The curve went through a sharp decline in 2014 due to his research. After 2015, he was “healthy” (60%-70%). As of 12/21/2017, his MI is 55.3% and GHSU is 56.1%. All of his previous lab test results confirmed with the diagram showing his chronic disease conditions are well under control.

Wael k. Ali is affiliated to General Secretary of EMROpharm forum-international pharmaceutical federation (FIP) and President of Egyptian organization of pharmacy, Egypt. Wael k. Ali is a recipient of many awards and grants for his valuable contributions and discoveries in major area of subject research. His international experience includes various programs, contributions and participation in different countries for diverse fields of study.

Passion for pharmacy innovation and their need to work combined with early age are the main reasons to make new pharmacy specialties grow very fast.

Christian Schäfer is a Full-Professor at the Department of Business Administration at Baden- Württemberg Cooperative State University Mannheim (DHBW) Germany. He teaches quantitative Methods, simulation in strategic forecasting and market research in healthcare. His research interests are in the fields of quantification of uncertainty, Patient-Behaviour- Modelling, and Partial Least Squares Structural Equation Modeling (PLS-SEM). Christian also runs special forecast-simulation and market research projects for the Pharmaceutical Industry. Prior to taking this role in 2015, Christian covered different Management and Director positions in Marketing, Competitive Intelligence, Strategic Forecasting and PM- Strategy within two International Pharmaceutical Company for 8 years.

His research interests are in the fields of quantification of uncertainty, Patient-Behaviour- Modelling, and Partial Least Squares Structural Equation Modeling (PLS-SEM). Christian also runs special forecast-simulation and market research projects for the Pharmaceutical Industry.

Prof. Dr. Gholamhossein Sodeifian (1971) graduated in chemical engineering (M.S) from University of Tehran, in 1997 and received his doctorate (Ph.D), in polymer engineering from Tarbiat Modares University, Tehran, in 2002. Prof. Sodeifian is currently academic member of Chemical Engineering Department of University of Kashan. His research group focused on extraction of essential and seed oils, solubility measurement of solid medicines, and micro- and nanoparticle formation of pharmaceutical materials in supercritical carbon dioxide (SCCO2) via various methods. He has also developed, for the first time in the world, a new and efficient technique for nanoparticle formation, i.e., ultrasonic assisted rapid expansion of supercritical solution into a liquid solvent (US-RESOLV). He has published more than 83 ISI scientific papers and several books. Furthermore, he has developed Sodeifian’s model for drugs solubility. Prof. Sodeifian has been assigned and included in the worlds’ top 2% of scientists list in 2021 and 2022.

His research group focused on extraction of essential and seed oils, solubility measurement of solid medicines, and micro- and nanoparticle formation of pharmaceutical materials in supercritical carbon dioxide (SCCO2) via various methods. He has also developed, for the first time in the world, a new and efficient technique for nanoparticle formation, i.e., ultrasonic assisted rapid expansion of supercritical solution into a liquid solvent (US-RESOLV).

Professor Jun O. Liu received his B.S. degree in Chemistry from Nanjing University. He went to the US through the Chemistry Graduate Program, obtaining his MS in organic chemistry from the Ohio State University and his PhD in biochemistry from MIT. He did his postdoc at Harvard University and served as a research associate at the NIH. He served as an assistant and associate professor of chemistry and biology at MIT Center for Cancer Research before moving to his current position as a professor of pharmacology and oncology at Johns Hopkins School of Medicine. His main research interest lies in the interface between chemistry, biology and medicine. In particular, his group has been focusing on the use of natural products and existing drugs as molecular probes of various cellular processes and as novel drug leads.

Our primary research interest lies at the interface between chemistry, biology and medicine. We employ high-throughput screening to identify modulators of various cellular processes and pathways that have been implicated in human diseases from cancer to autoimmune diseases. Once biologically active compounds are identified, they will serve as both probes of the biological processes of interest and leads for the development of new drugs for treating human diseases. Among the biological processes of interest are cancer cell growth and mestastasis, apoptosis, angiogenesis, calcium-dependent signaling pathways, eukaryotic transcription and translation. Some of the ongoing projects are highlighted herein.

Dr. Emmanuel O. Akala received his B. Pharm. and M.Sc.(Pharmaceutics) from The University of Ife (now OAU) Nigeria and Ph.D. (Pharmaceutics) from The University of Manchester, England. He was a DAAD Research Scientist in Biopharmaceutics and Pharmaceutical Technology at The University of Munster, Germany, NIH-Fogarty International Fellow in Pharmaceutics and Bioengineering at The University of Utah (USA). He is a registered and immunization Pharmacist in Utah, Maryland and Washington DC.

Dr. Akala’s research interest is in novel and conventional drug products’ design and development. Current research efforts focus on Nanotechnological Platforms for the Delivery of Bioactive (Drugs) and Diagnostic Agents.

Dr Irina Ermolina is a senior lecturer in Pharmaceuticals in the School of Pharmacy, De Montfort University. She gained her PhD degree in Molecular Physics in Institute of Biochemistry and Biophysics, Russian Academy of Sciences, Kazan, Russia. Prior to joining the DMU as an academic staff, Dr Ermolina was employed as Postdoctoral Research Fellow at Glasgow University and Southampton University. Previously she worked as a senior researcher in Institute of Biochemistry and Biophysics, Kazan, Russian Academy of Sciences. Dr Ermolina now specializes in characterization of physical properties of pharmaceutical solids and powders studied by different analytical techniques; development and characterization of hydrogels as drug delivery systems; dielectric properties biological systems (proteins, DNA, cells, disaccharides); stability characterization of freeze-dried pharmaceuticals; the dynamic structure of proteins in solutions and membrane films.

Freeze-drying Pharmaceuticals Dielectric spectroscopy Thermoanalytical methods Terahertz spectroscopy Characterization of hydrogels.